Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Equipe Genetique des Anomalies du Developpement, |
RCV003153965 | SCV003843218 | pathogenic | See cases | 2020-08-28 | criteria provided, single submitter | clinical testing | |
Equipe Genetique des Anomalies du Developpement, |
RCV002246256 | SCV001439342 | pathogenic | Brain small vessel disease 1 with or without ocular anomalies | 2020-08-28 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004727057 | SCV005337410 | likely pathogenic | COL4A1-related disorder | 2024-05-13 | no assertion criteria provided | clinical testing | The COL4A1 c.4843G>A variant is predicted to result in the amino acid substitution p.Glu1615Lys. This variant has been reported as de novo in an individual with COL4A1/2-related brain defects, which were observed both during prenatal and postnatal development (Itai et al. 2021. PubMed ID: 32732225). This variant has also been observed in an individual (inheritance not determined) with bilateral porencephaly and other COL4A1-related symptoms (Yoneda et al. 2013. PubMed ID: 23225343; Nakamura et al. 2021. PubMed ID: 34281745). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as likely pathogenic. |